08 January 2019 : Clinical Research
Effects of Intermittent Parathyroid Hormone 1–34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic WomenYutao Tang1ACE, Han Xia1B, Liang Kang1F, Quan Sun1D, Zhe Su1G, Congqiang Hao1F, Yuan Xue1AG*
Med Sci Monit 2019; 25:259-268
BACKGROUND: Intermittent parathyroid hormone (PTH) 1–34 administration stimulates osteogenesis and increases bone marrow mesenchymal stem cell (MSC) density; however, its effect on the circulating MSCs is unknown. This study aimed to examine the effect of intermittent PTH 1–34 administration on circulating MSCs in the peripheral blood of postmenopausal osteoporotic women.
MATERIAL AND METHODS: Fifty-four postmenopausal osteoporotic women at high risk of fracture were enrolled and administered either teriparatide (PTH 1–34) or alendronate for 12 months. Whole blood samples were obtained at baseline, 1, 3, 6, and 12 months after initiation of treatment. Flow cytometry analyses were performed to identify circulating MSCs (CD73+, CD90+, CD105+, CD34−, and CD45−). Serum markers of bone formation, bone resorption, as well as bone mineral density (BMD) were serially measured. Circulating MSCs were isolated from peripheral blood of teriparatide treated women and cultured in osteogenic medium to examine their osteogenic differentiation potential.
RESULTS: Teriparatide treatment increased circulating MSCs to 141±96% (P<0.001) by month 1, persisting until month 12; this increase was positively associated with increases in bone formation and bone resorption biomarkers (at month 6) and spine BMD (at month 12). Furthermore, intermittent PTH 1–34 administration promoted in vitro osteogenic differentiation of circulating MSCs, evident from increased alkaline phosphatase (ALP) activity, ALP-expressing cell density, calcium deposition, and Runx-2, OSX, COL 1a1, and osteocalcin mRNA upregulation.
CONCLUSIONS: Intermittent PTH 1–34 administration increased circulating MSC density in women with postmenopausal osteoporosis and enhanced in vitro osteogenic differentiation potential of these cells.
Keywords: alendronate, mesenchymal stromal cells, Osteoporosis, Postmenopausal, Parathyroid Hormone
01 January 2022 : EditorialEditorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients
Med Sci Monit 2022; 28:e935952
11 January 2022 : Clinical ResearchA Remote Questionnaire-Based Study to Compare Alcohol Use in 1030 Final-Year High School Students in Split-...
Med Sci Monit In Press; DOI: 10.12659/MSM.935567
08 November 2021 : Database AnalysisVirtual Screening and Molecular Docking to Study the Mechanism of Chinese Medicines in the Treatment of Cor...
Med Sci Monit In Press; DOI: 10.12659/MSM.934102
31 December 2021 : Clinical ResearchA Prospective Observational Study of 42 Patients with COVID-19 infection and a History of Hepatitis C Virus...
Med Sci Monit 2021; 27:e935075
19 Jan 2022 : Clinical ResearchA Retrospective Study to Compare the Effects of Methylprednisolone and Dexamethasone in 35 Patients with An...
Med Sci Monit In Press; DOI: 10.12659/MSM.934703
17 Jan 2022 : Clinical ResearchUnveiling the Differences in Biological Properties of Dental Pulp Stem Cells from Normal and Inflamed Pulp:...
Med Sci Monit In Press; DOI: 10.12659/MSM.934511
14 Jan 2022 : Database AnalysisIdentification of Key Genes Associated with Brain Metastasis from Breast Cancer: A Bioinformatics Analysis
Med Sci Monit In Press; DOI: 10.12659/MSM.935071
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
01 Nov 2020 : Review articleLong-Term Respiratory and Neurological Sequelae of COVID-19
Med Sci Monit 2020; 26:e928996
05 Mar 2020 : Clinical ResearchThe Effects of Social Support on Sleep Quality of Medical Staff Treating Patients with Coronavirus Disease ...
Med Sci Monit 2020; 26:e923549